The best strategy for identifying pelvic masses and triaging patients to the appropriate surgeons.
In a unanimous vote, a Food and Drug Administration (FDA) advisory committee has recommended that the agency give premarket approval to a human papillomavirus (HPV) DNA test as first-line screening for cervical cancer.
A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
Ovarian cancer is notorious for its late stage at diagnosis and its poor prognosis. In the absence of good screening tests, salpingectomy is the only form of prophylaxis for this cancer.
Adding a monoclonal antibody (MAb)—bevacizumab—to combination chemotherapy may increase survival in patients with recurrent cervical cancer, according to results of a National Cancer Institute-funded randomized trial. Use of bevacizumab in cervical cancer is experimental; the MAb currently is approved to treat metastatic colorectal cancer, non-squamous, non-small cell lung cancer, and glioblastoma.
A daily regimen of low-dose (
A small, preliminary study suggests that measurement of heat changes in blood proteins may have potential in detection and staging of cervical cancer. Published in PLoS One, the report describes what may be a unique plasma thermal profile for different disease stages that could help distinguish them from healthy tissue.
A screening protocol that takes into consideration CA-125 levels over time and results of transvaginal ultrasound (TVS) shows promise in early detection of ovarian cancer, according to a new report from investigators at the University of Texas MD Anderson Cancer Center. In a large, prospective study, the combination demonstrated excellent specificity and positive predictive value (PPV) in a group of women at average risk of ovarian cancer.